A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HESS, Connie N. et al. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, v. 246, p. 136-143, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2021.12.010. Acesso em: 18 ago. 2024.
APA
Hess, C. N., Capell, W. H., Bristow, M. R., Ruf, W., Szarek, M., Morrow, D. A., et al. (2022). Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American heart journal, 246, 136-143. doi:10.1016/j.ahj.2021.12.010
NLM
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010
Vancouver
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial [Internet]. American heart journal. 2022 ; 246 136-143.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1016/j.ahj.2021.12.010
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EISEN, Alon et al. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, v. 63, n. 1, p. 307-315, 2017Tradução . . Disponível em: https://doi.org/10.1373/clinchem.2016.264788. Acesso em: 18 ago. 2024.
APA
Eisen, A., Bonaca, M. P., Scirica, B. M., White, H. D., Tendera, M., Dellborg, M., et al. (2017). High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial. Clinical Chemistry, 63( 1), 307-315. doi:10.1373/clinchem.2016.264788
NLM
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
Vancouver
Eisen A, Bonaca MP, Scirica BM, White HD, Tendera M, Dellborg M, Nicolau JC, Morais J, Fox KAA, Bohula EA, Murphy SA, Braunwald E, Morrow DA. High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial [Internet]. Clinical Chemistry. 2017 ; 63( 1): 307-315.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1373/clinchem.2016.264788
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGNANI, Giulia et al. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, v. 4, n. art., p. 9 2015, 2015Tradução . . Disponível em: https://doi.org/10.1161/JAHA.114.001505. Acesso em: 18 ago. 2024.
APA
Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., et al. (2015). Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. Journal of the American Heart Association, 4( art.), 9 2015. doi:10.1161/JAHA.114.001505
NLM
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1161/JAHA.114.001505
Vancouver
Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States [Internet]. Journal of the American Heart Association. 2015 ; 4( art.): 9 2015.[citado 2024 ago. 18 ] Available from: https://doi.org/10.1161/JAHA.114.001505
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MORROW, David A. et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. Journal of the american heart association, v. 119, n. 21, p. 2758-2764, 2009Tradução . . Acesso em: 18 ago. 2024.
APA
Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., et al. (2009). Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. Journal of the american heart association, 119( 21), 2758-2764.
NLM
Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Farias A, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. Journal of the american heart association. 2009 ; 119( 21): 2758-2764.[citado 2024 ago. 18 ]
Vancouver
Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Farias A, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. Journal of the american heart association. 2009 ; 119( 21): 2758-2764.[citado 2024 ago. 18 ]
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIRALDEZ, Roberto R. et al. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an extract-timi 25 analysis. Drugs, v. 69, n. 11, p. 1433-1443, 2009Tradução . . Acesso em: 18 ago. 2024.
APA
Giraldez, R. R., Wiviott, S. D., Nicolau, J. C., Mohanavelu, S., Morrow, D. A., Antman, E. M., & Giugliano, R. P. (2009). Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an extract-timi 25 analysis. Drugs, 69( 11), 1433-1443.
NLM
Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an extract-timi 25 analysis. Drugs. 2009 ; 69( 11): 1433-1443.[citado 2024 ago. 18 ]
Vancouver
Giraldez RR, Wiviott SD, Nicolau JC, Mohanavelu S, Morrow DA, Antman EM, Giugliano RP. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an extract-timi 25 analysis. Drugs. 2009 ; 69( 11): 1433-1443.[citado 2024 ago. 18 ]